PFS, OS or toxicity: What is the most important factor in the treatment of EGFR-mutated lung cancer?

In recent years, many studies on first line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer have been published. The main axis of the studies are the FALURA and FLAURA2 studies including osimertinib, and the MARIPOSA study of amivantamab plus lazertinib has been published. In addition, the RELAY and RAMOSE trials of EGFR - tyrosine kinase inhibitor plus angiogenesis inhibitors have been published. The effects of amivantamab is as brilliant as "butterflies", and we look forward to the day when it is available in Japan. However, it has more adverse events when compared to osimertinib 1, and needs to be used in selected patients. While patients and physicians will be pleased to have many options, we are still struggling with the question of which is the most appropriate. Although overall survival data are being published, they are immature, and no conclusions can be drawn yet.